

+86-25- 3608-605

FORM D RECEIVED 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, **SECTION 4(6), AND/OR** UNIFORM LIMITED OFFERING EXEMPTIO

( check if this is an amendment and name has changed, and indicate change.)

OMB APPROVAL							
OMB Number:	3235-0076						
Expires:	May 31, 2005						
Estimated average burden							
hours per respo	nse 16.00						

SEC USE ONL

Prefix

CECTION 4(C) AND (OD	
SECTION 4(6), AND/OR	DATE RECEIVED
IFORM LIMITED OFFERING EXEMP	TION
amendment and name has changed, and indicate change.)	
nc. Convertible Promissory Note	
	ULOE
endment	
A. BASIC IDENTIFICATION DATA	
he issuer	
endment and name has changed, and indicate change.)	
c.	
(Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)
e Street, Wilmington, Delaware,	
(Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)

Brief Description of Business Development and manufacture of biopharmaceutical products in China

Corporation Trust Center, 1209 Orange Street, Wilmington, Delaware,

China Biopharmaceuticals Holdings, Inc. Convertible Promissory Note

Name of Issuer ( check if this is an amendment and name has changed, and indicate change.)

New Filing Amendment

Enter the information requested about the issuer

C/O Nanjing Keyuan 139 Ma Tai Street, Nanjing F4

PROCESSED	9
-----------	---

				- 2 4 6 4 6 4 6 2 C 2 C 2
Type of Business Organization				
corporation	limited parti	nership, already for	ned other (please spe	cify): APR 1 4 2005
business trust	limited parts	nership, to be forme	d	2002 L 1 1 2003
		• • • • • • • • • • • • • • • • • • • •		TUNG
		Month Year	•	THOMSON
Actual or Estimated Date of Incorp	oration or Organization	0 8 7	6 Actual Estimated	FINANCIAL
Jurisdiction of Incorporation or Or	ganization: (Enter two-	letter U.S. Postal S	ervice abbreviation for State:	THE STORY
	CN for C	anada: FN for other	foreign jurisdiction)	

### GENERAL INSTRUCTIONS

#### Federal:

Name of Offering

Type of Filing:

Filing Under (Check box(es) that apply):

China Biopharmaceuticals Holdings, Inc.

Address of Principal Business Operations

(if different from Executive Offices)

Address of Executive Offices

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C.

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where To File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

#### State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION -

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predictated on the filing of a federal notice.

> Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

		A: BASIC I	DENTI	FICATION DATA	5 ( ) I.		
<ul><li>Each beneficial ow</li><li>Each executive off</li></ul>	the issuer, if the issuer having the pow	uer has been organized	direct th	e vote or disposition			es of equity securities of the issuer. ership issuers; and
Check Box(es) that Apply:	Promoter	Beneficial Owne	r 🗹	Executive Officer	V	Director	General and/or Managing Partner
Full Name (Last name first, An Lu Fan Business or Residence Addre	,	St					
Suite 1104 Building 25 J			Code)				
Check Box(es) that Apply:	Promoter	Beneficial Owne	r 🗾	Executive Officer		Director	General and/or Managing Partner
Full Name (Last name first, Liu Xiao Hao	f individual)						
Business or Residence Addre Suite 304 2 Yuquan Road			Code)				
Check Box(es) that Apply:	Promoter	Beneficial Owne	ı 🛭	Executive Officer		Director	General and/or Managing Partner
Full Name (Last name first, Zhang, Luyong	f individual)		<del></del>				 
Business or Residence Addressuite 2-302, Building 4, 4		•	Code)		-		
Check Box(es) that Apply:	Promoter	Beneficial Owne	r 💆	Executive Officer	V	Director	General and/or Managing Partner
Full Name (Last name first, Mao Peng Chris	if individual)				<u> </u>		
Business or Residence Addre P.O. Box 151 Fo Shan	`	Street, City, State, Zip xia District Jinan F4		1		<del></del>	
Check Box(es) that Apply:	Promoter	Beneficial Owne	r 🗾	Executive Officer		Director	General and/or Managing Partner
Full Name (Last name first, Huang Chen Tai	if individual)			·····			
Business or Residence Addre P.O Box 307, 4885 King	•	Street, City, State, Zip A1 V5H4T2	Code)				
Check Box(es) that Apply:	Promoter	Beneficial Owne	ır 🗌	Executive Officer		Director	General and/or Managing Partner
Full Name (Last name first,	if individual)					·	 
Business or Residence Addre	ess (Number and	Street, City, State, Zip	Code)				
Check Box(es) that Apply:	Promoter	Beneficial Owner	r 🗌	Executive Officer		Director	General and/or Managing Partner
Full Name (Last name first,	if individual)						 
Business or Residence Address	ess (Number and	Street, City, State, Zip	Code)				 

1			en de la companya de La companya de la co		B. P	FORMATI	ON ABOU	T OFFERI	NG.			, A	
1. Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?								Yes	No				
1.	•												
2.	Answer also in Appendix, Column 2, if filing under ULOE.  2. What is the minimum investment that will be accepted from any individual?									s 1.0	3		
						pre	, <b>.</b>		•••••		•••••	Yes	No
3.	Does the	offering p	permit joint	ownershi	p of a sing	le unit?							×
4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.													
Ful	l Name (I	ast name	first, if indi	vidual)									
Bu	siness or I	Residence	Address (N	umber and	Street, Ci	ty, State, Z	ip Code)						
		ociated Br rtners, Inc	oker or De	aler									
			Listed Has	Solicited	or Intends	to Solicit I	Purchasers					·	
	(Check	'All States	" or check	individual	States)		•••••		••••••			☑ Al	States
	AL IL MT RI	AK IN NE SC	AZ IA NV SD	AR KS NH TN	CA KY NJ TX	CO LA NM UT	CT ME NY VT	DE MD NC VA	MA ND WA	FL MI OH WV	GA MN OK WI	MS OR WY	MO PA PR
Ful	Il Name (I	ast name	first, if ind	ividual)	<del></del> ··								
Bu	siness or	Residence	Address (?	Number an	d Street, C	ity, State, 2	Zip Code)						
Na	me of Ass	ociated Br	oker or De	aler									
Sta	ites in Wh	ich Person	Listed Has	s Solicited	or Intends	to Solicit	Purchasers	<del></del>				,-a,	
	(Check	"All States	s" or check	individual	States)	•••••						All States	
	AL IL MT RI	AK IN NE SC	AZ IA NV SD	AR KS NH TN	CA KY NJ TX	CO LA NM UT	CT ME NY VT	DE MD NC VA	DC MA ND WA	FL MI OH WV	GA MN OK WI	MS OR WY	ID MO PA PR
Fu	ll Name (l	ast name	first, if ind	ividual)									
Bu	siness or	Residence	Address (1	Number an	d Street, C	City, State,	Zip Code)			<del> </del>			
Name of Associated Broker or Dealer													
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers  (Check "All States" or check individual States)							. All States						
	AL IL MT	AK IN NE SC	IA NV SD	AR KS NH TN	CA KY NJ	CO LA NM UT	CT ME NY VT	DE MD NC VA	DC MA ND WA	FL MI OH WV	GA MN OK WI	HI MS OR WY	ID MO PA PR

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

# C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if the answer is "none" or "zero." If the transaction is an exchange offering, check this box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.		
	Type of Security	Aggregate Offering Price	Amount Already Sold
	Debt	S	\$
	Equity		s
	Common Preferred		
	Convertible Securities (including warrants)	500,000.00	\$500,000.00
	Partnership Interests		\$
	Other (Specify)		\$
	Total		§ 500,000.00
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	20	\$ 500,000.00
	Non-accredited Investors	0	\$_0.00
	Total (for filings under Rule 504 only)	20	\$ 500,000.00
	Answer also in Appendix, Column 4, if filing under ULOE.		
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C — Question 1.		
	Type of Offering	Type of Security	Dollar Amount Sold
	Rule 505		\$
	Regulation A		\$
	Rule 504	Convertible Note	
	Total		\$_500,000.00
4	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the insurer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		\$
	Printing and Engraving Costs		\$
	Legal Fees	<b>v</b>	\$_10,000.00
	Accounting Fees		\$
	Engineering Fees		\$
	Sales Commissions (specify finders' fees separately)	<b></b>	\$_40,000.00
	Other Expenses (identify)		\$
	Total	П	\$ 50,000.00

	C. OFFERING PRICE, NUME	BER OF INVESTORS, EXPENSES AND USE OF P	ROCEEDS	
	b. Enter the difference between the aggregate offeri and total expenses furnished in response to Part C — proceeds to the issuer."		رحشن گنسیت درگینگسیبیبیین	450,000.00 \$
5.	Indicate below the amount of the adjusted gross pro each of the purposes shown. If the amount for any check the box to the left of the estimate. The total of proceeds to the issuer set forth in response to Part	y purpose is not known, furnish an estimate and the payments listed must equal the adjusted gross		
			Payments to Officers, Directors, & Affiliates	Payments to Others
	Salaries and fees	[	]\$	\$
	Purchase of real estate	[	\$	
	Purchase, rental or leasing and installation of mac and equipment			. 🗆 \$
	Construction or leasing of plant buildings and faci	ilities[	_ \$	. 🗆 \$
	Acquisition of other businesses (including the value offering that may be used in exchange for the asset issuer pursuant to a merger)	ts or securities of another	¬ \$	□ \$
	Repayment of indebtedness			
	Working capital			
	Other (specify):			
	other (specify).			
		[	]\$	
	Column Totals		\$ 0.00	\$ 450,000.00
	Total Payments Listed (column totals added)		\$_ <del>4</del>	50,000.00
		D. FEDERAL SIGNATURE	ti di dina	
sigi	e issuer has duly caused this notice to be signed by the nature constitutes an undertaking by the issuer to fur information furnished by the issuer to any non-acc	nish to the U.S. Securities and Exchange Commis	sion, upon writte	
Issı	uer (Print or Type)	Signature Den Man	Date	
Ch	nina Biopharmaceuticals Holdings, Inc.	7	April 1st, 2005	
Nat	me of Signer (Print or Type)	Title of Signer (Print or Type)		- Mao
Chr	is Peng Mao	CEO & Chairman of Board		2/100
				<del></del>

## - ATTENTION ----